Condition

Early Rheumatoid Arthritis

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 8 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials8

Recruiting0

Common interventions16

Lead sponsors shown6

Clinical trials

8 shown

A Randomized Clinical Trial Evaluating the Efficacy of Clinical Pharmacist Assistance Along With Pharmaceutical and Non-pharmaceutical Therapy in the Early Rheumatoid ArthritisNCT07726355 · 2025-04-10

COMPLETED

Trial of Ginsenoside Compound K (GCK) Tablet in Patients With Rheumatoid ArthritisNCT03755258 · 2017-03-16

UNKNOWN

Power Doppler in Hand Joints of Early RA PatientsNCT04752748 · 2014-08-01

COMPLETED

Early RA MRI Early Intensive Treatment StudyNCT01762176 · 2012-10-01

COMPLETED

Early RA Vascular Randomised Controlled StudyNCT01768923 · 2012-10-01

COMPLETED

Study to Determine the Effects of Different Doses of Methotrexate (MTX) When Taken With Adalimumab in Subjects With Early Rheumatoid Arthritis (RA)NCT01185301 · 2010-10-01

COMPLETED

INCMNSZ - Rheumatoid Arthritis CohortNCT03389711 · 2004-02-04

UNKNOWN

Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid ArthritisNCT00195663 · 2000-12-01

COMPLETED

Common interventions

adalimumabBIOLOGICAL2 methotrexateDRUG2 Adalimumab placeboBIOLOGICAL1 Clinical Pharmacist Led InterventionOTHER1 DMARD TherapyDRUG1 DMARD´s and multidisciplinary treatmentCOMBINATION_PRODUCT1 Drug protocolDRUG1 GCK 100 mg + Placebo 200 mgDRUG1 GCK 200 mg + Placebo 100 mgDRUG1 GCK 300 mgDRUG1 Methotrexate placeboDRUG1 Minimal disease activity remissionPROCEDURE1 Placebo 300mgDRUG1 Protocolized intensive treatmentPROCEDURE1 SDAI remissionPROCEDURE1 Usual carePROCEDURE1

Leading sponsors

AbbVie (prior sponsor, Abbott) 2 Chinese University of Hong Kong 2 Deraya University 1 Federal University of São Paulo 1 National Institute of Medical Sciences and Nutrition, Salvador Zubiran 1 Zhejiang Hisun Pharmaceutical Co. Ltd. 1

Trial status mix

COMPLETED6

UNKNOWN2

Phase mix

PHASE33

NA2

PHASE11

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.